Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases
Shots:
- Regeneron and Mammoth signed a collaboration to develop and commercialize in vivo CRISPR-based gene editing therapies by using Regeneron’s AAV and antibody engineering and Mammoth’s ultracompact gene editing systems
- Under agreement, Mammoth will receive $100M includes $95M upfront cash and equity, $370M R&D and commercial milestones per target, plus single digits to mid-teens royalties, with an option to receive co-funding and profit-sharing on majority of collaborative initiatives in exchange of milestones and royalties
- Regeneron get access to Mammoth’s editing technologies, other than certain excluded targets for 5.5yrs; option to extend access for additional 2yrs upon research extension fee payment; both companies will discover targets
Ref: Regeneron | Image: Regeneron
Related News:-
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
